Drugs in Inflammation (1991)

Reducing the Side-Effects of Anti-Inflammatory Drugs.- Towards safer nonsteroidal anti-inflammatory drugs.- Developing nonsteroidal anti-inflammatory drugs (NSAIDs) with decreased gastrointestinal (GI) toxicity.- Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.- A new anti-inflammatory agent (EGIS-5645) without gastrointestinal side-effect.- Antipyretic activity of tebufelone (NE-11740) in man.- Steroid-saving potency of nonsteroidal anti-inflammatory agents - a reevaluation with the new agent CGP 28238 in rat inflammatory models.- A biochemical investigation of auranofin nephrotoxicity by high field proton nuclear magnetic resonance (NMR) spectroscopy.- Influence of an intravenous dose of aurothiomalate on the status of low-molecular-mass endogenous metabolites in blood plasma: a proton nuclear magnetic resonance (NMR) study.- Influence of disodium aurothiomalate on the activities of xanthine dehydrogenase and xanthine oxidase in endothelial cells.- Application of a novel 1:1 gold (I)-chromophoric thiolate complex as a spectrophotometric probe for the thiol-exchange reactions of anti-arthritic gold drugs in biological fluids.- Effects of auranofin on endothelium dependent contractions in isolated rat aoria.- New Approaches to Pain Relief.- Electrophysiological mechanisms in inflammatory pain.- Molecular base of acetylcholine and morphine analgesia.- Prostaglandin (PG) modulation of bradykinin-induced hyperalgesia and oedema in the guinea-pig paw - effects of PGD2, PGE2 and PGI2.- Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.- Pharmacological profile of flupirtine, a novel centrally acting, non-opioid analgesic drug.- The pharmacological profile of aceclofenac, a new nonsteroidal anti-inflammatory and analgesic drug.- New Treatments for Bone and Cartilage Loss in Rheumatoid Arthritis.- Molecular basis of intracellular interactions in relation to bone and joint disease.- The role of proteinases in cartilage destruction.- Recognition of IL1-activated chondrocytes in porcine articular cartilage.- In vivo evidence for a key role of IL-1 in cartilage destruction in experimental arthritis.- An anti-CD4 antibody for treatment of chronic inflammatory arthritis.- Modulation of splenic lymphocyte activities by a new hypoxanthine derivative (ST 789) in immunosuppressed mice.- The newly developed neutrophil oxidative burst antagonist apocynin inhibits joint-swelling in rat collagen arthritis.- Auto-immune spondylodiscitis associated with collagen induced arthritis in rats: high field MRI findings.- Influence of muramyl dipeptide on established experimental arthritis in rats.- Selective inhibition by magnosalin and magnoshinin, compounds from shin-I (Flos magnoliae), of adjuvant-induced angiogenesis and granuloma formation in the mouse pouch.- Drug Modulation of Cytokine Production.- Cellular and molecular mechanisms of cytokine networking.- Anti-inflammatory properties of E5090, a novel orally active inhibitor of IL-1 generation.- A novel inhibitor of IL-1 generation, E5090: in vitro inhibitory effects on the generation of IL-1 by human monocytes.- A novel inhibitor of IL-1 generation, E5090: in vivo inhibitory effects on the generation of IL-1-like factor and on granuloma formation in an air-pouch model.- Lack of adjuvanticity of human recombinant interleukin-lss in collagen induced arthritis in rats.- Influence of azelastine on IL-1ss generation in vitro and IL-lss-induced effect in vivo.